Alde Medi Impex Ltd. IPO Details
Alde Medi Impex was incorporated on March 5, 1997. The company markets, brands and distributes pharmaceutical and nutraceutical products across domestic and international markets, covering ethical, OTC/generic, critical care and nutraceutical products in various dosage forms. Its portfolio spans multiple therapeutic categories, including anti-infectives, cardiology, gastroenterology, neurology, ophthalmology, orthopaedics, paediatrics and metabolic disorders
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.7 M | - | - | ₹0 | DRHP DOC |
Alde Medi Impex issue details
Alde Medi Impex has 4.7 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Alde Medi Impex IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE |
Alde Medi Impex NUMBER OF SHARES ON OFFER
Alde Medi Impex FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY26 | 105.2 | 13.0 | 3.8 | -4.9 | 18.2% |
| FY25 | 80.6 | 4.7 | -3.9 | -5.2 | 10.6% |
| FY24 | 58.6 | -0.8 | -7.3 | -7.6 | 2.8% |
Alde Medi Impex INFORMATION ON IPO ISSUE
About Alde Medi Impex
Alde Medi Impex was incorporated on March 5, 1997. The company markets, brands and distributes pharmaceutical and nutraceutical products across domestic and international markets, covering ethical, OTC/generic, critical care and nutraceutical products in various dosage forms. Its portfolio spans multiple therapeutic categories, including anti-infectives, cardiology, gastroenterology, neurology, ophthalmology, orthopaedics, paediatrics and metabolic disorders
Object of the Issue
- Repayment and/or pre-payment, in full or part, of certain borrowings availed by the company
- To meet working capital requirements
- General corporate purposes
Alde Medi Impex - PROMOTERS
| Name |
|---|
| Rajesh Kumar Rastogi |
| Manas Rastogi |
| Mehul Rastogi |
| Nisha Rastogi |
Alde Medi Impex - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Rajesh Kumar Rastogi | Chairman & Whole time Director |
| Manas Rastogi | Managing Director |
| Mehul Rastogi | Whole time Director |
| Sanjeev Sharma | Independent Director |
| Niyati Prashant Rathod | Independent Director |
| Nitish Khaitan | Independent Director |
Alde Medi Impex Book Running Lead Manager
Corporate Professionals Capital Private Limited
aldemedi.ipo@indiacp.com
Alde Medi Impex Registrar to the Offer
Kfin Technologies Limited
aldemedi.ipo@kfintech.com
Alde Medi Impex Strengths
Asset-light business model
The company follows an asset-light model and does not own manufacturing facilities, with its pharmaceutical products manufactured by third-party partners under contract manufacturing or loan licence arrangements. This model reduces capital expenditure while requiring effective management of manufacturing partners, including their capacity, quality, regulatory compliance and continuity of supply
Diversified product portfolio
The company offers prescription, OTC/generic, critical care and nutraceutical products across dosage forms such as tablets, capsules, injections, syrups, powders, ointments, creams and drops. Its portfolio covers therapeutic categories including anti-infectives, cardiology, gastroenterology, gynaecology, neurology, ophthalmology, orthopaedics, paediatrics and metabolic disorders
Quality assurance & control
The company maintains dedicated Quality Assurance and Quality Control functions to oversee product quality across its third-party manufacturing arrangements, including partner evaluation, audits, documentation, testing and quality monitoring. It also tracks quality complaints and regulatory matters and coordinates corrective actions with manufacturers to maintain quality standards and compliance
Alde Medi Impex Risks
Overseas product registration risks
The company’s overseas sales depend on obtaining product registrations or marketing authorisations from local regulators, which may involve lengthy processes, additional costs and inspections of third-party manufacturing facilities. Delays, refusals, renewal issues or non-compliance could postpone or prevent market entry and revenue generation, and adversely affect its business and financial performance
Counterfeit product risks
The company’s products may be exposed to counterfeiting through multi-tier distribution networks in India and overseas, over which it has limited control and monitoring ability. Counterfeit products bearing its brands could result in regulatory or legal action, customer concerns and reputational damage, even where the company is not involved in their manufacture or distribution
IT & cybersecurity risks
The company relies on IT systems for order processing, inventory management, accounting and regulatory documentation, while storing commercially sensitive information relating to customers, distributors and manufacturing partners. System failures or cyberattacks could disrupt operations, expose sensitive data and result in reputational, regulatory or legal consequences, although no material IT disruption or cybersecurity breach affected its operations during the last three Financial Years
IPO FAQs
The promoters of the company are Rajesh Kumar Rastogi, Manas Rastogi, Mehul Rastogi and Nisha Rastogi.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.